- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06848075
Une étude de phase IIB, randomisée, en double aveugle, contrôlée par placebo de l'eLISMETREP (K-304) dans le traitement de la migraine
Une étude de phase IIB, randomisée, en double aveugle, contrôlée par placebo de l'elismmetrep (K-304) dans le traitement de la migraine: une gamme de doses sera évaluée
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35205
- Central Research Associates, LLC (CRA) dba Flourish Research
-
Mobile, Alabama, États-Unis, 36608
- AMR Mobile
-
-
Arizona
-
Tucson, Arizona, États-Unis, 85710
- Wake Research/ Tucson Neuroscience Research
-
-
California
-
Canoga Park, California, États-Unis, 91303
- Hope Clinical Research
-
Encino, California, États-Unis, 91316
- WR-PRI, LLC (Encino)
-
Huntington Beach, California, États-Unis, 92647
- Marvel Clinical Research
-
La Mesa, California, États-Unis, 91942
- Eximia Research - CA
-
Lemon Grove, California, États-Unis, 91945
- Synergy San Diego
-
Newport Beach, California, États-Unis, 92660
- WR-PRI, LLC (Newport Beach)
-
Oceanside, California, États-Unis, 92056
- Excell Research, Inc.
-
Pomona, California, États-Unis, 91767
- Empire Clinical Research
-
Riverside, California, États-Unis, 92503
- Artemis Institute for Clinical Research - Riverside
-
San Diego, California, États-Unis, 89109
- Acclaim Clinical Research
-
San Diego, California, États-Unis, 92103
- Artemis Institute for Clinical Research - San Diego
-
Walnut Creek, California, États-Unis, 94598
- Diablo Clinical Research, Inc.
-
West Hills, California, États-Unis, 91307
- Focus Clinical Research
-
-
Connecticut
-
Cromwell, Connecticut, États-Unis, 06416
- CT Clinical Research
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30329
- DelRicht Research
-
Stockbridge, Georgia, États-Unis, 30281
- Clinical Research Atlanta - Stockbridge
-
-
Idaho
-
Boise, Idaho, États-Unis, 83704
- Northwest Clinical Trials
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60607
- Cedar Crosse Research Center
-
Flossmoor, Illinois, États-Unis, 60422
- Healthcare Research Network II, LLC
-
-
Kansas
-
Overland Park, Kansas, États-Unis, 66202
- Collective Medical Research
-
Wichita, Kansas, États-Unis, 67207
- Alliance for Multispecialty Research
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40213
- L-MARC Research Center
-
-
Louisiana
-
Chalmette, Louisiana, États-Unis, 70043
- Crescent City Headache & Neurology Center
-
New Orleans, Louisiana, États-Unis, 70115
- DelRicht Research
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48104
- Michigan Head Pain and Neurological Institute
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55402
- Clinical Research Institute
-
-
Mississippi
-
Gulfport, Mississippi, États-Unis, 39503
- DelRicht Research
-
-
Missouri
-
Hazelwood, Missouri, États-Unis, 63042
- Healthcare Research Network
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89109
- Excel Clinical Research
-
North Las Vegas, Nevada, États-Unis, 89119
- Las Vegas Clinical Trials
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87102
- Albuquerque Clinical Trials, Inc.
-
-
New York
-
Amherst, New York, États-Unis, 14226
- Dent Neurosciences Research Center
-
Manlius, New York, États-Unis, 13104
- CNY Clinical Research
-
Rochester, New York, États-Unis, 14609
- Rochester Clinical Research
-
Williamsville, New York, États-Unis, 14221
- Upstate Clinical Research Associates LLC
-
-
North Carolina
-
Greensboro, North Carolina, États-Unis, 27405
- Headache Wellness Center
-
High Point, North Carolina, États-Unis, 27260
- Peters Medical Research
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45212
- CTI Clinical Research Center
-
-
Oklahoma
-
Edmond, Oklahoma, États-Unis, 73034
- OK Clinical Research, LLC
-
Oklahoma City, Oklahoma, États-Unis, 73102
- Hightower Clinical
-
Tulsa, Oklahoma, États-Unis, 74133
- DelRicht Research
-
Yukon, Oklahoma, États-Unis, 73099
- Tekton Research
-
-
Oregon
-
Portland, Oregon, États-Unis, 97210
- Summit Research Network
-
-
Pennsylvania
-
Allentown, Pennsylvania, États-Unis, 18103
- Lehigh Center for Clinical Research
-
Philadelphia, Pennsylvania, États-Unis, 19114
- Clinical Research Philadelphia, LLC
-
Scottdale, Pennsylvania, États-Unis, 15683
- Frontier Clinical Research, LLC
-
Smithfield, Pennsylvania, États-Unis, 15478
- Frontier Clinical Research, LLC
-
West Chester, Pennsylvania, États-Unis, 19380
- Atlas-Clinical
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29406
- Clinical Trials of South Carolina
-
North Charleston, South Carolina, États-Unis, 29405
- Coastal Carolina Research Center
-
-
Tennessee
-
Chattanooga, Tennessee, États-Unis, 37421
- WR-ClinSearch
-
Knoxville, Tennessee, États-Unis, 37909
- AMR Knoxville (Formerly NOCCR)
-
Nashville, Tennessee, États-Unis, 37203
- Clinical Research Associates, Inc.
-
-
Texas
-
Austin, Texas, États-Unis, 78745
- Tekton Research
-
Austin, Texas, États-Unis, 78737
- Donald J Garcia Jr, MD, PA
-
Dallas, Texas, États-Unis, 75251
- FutureSearch Trials of Dallas, LP
-
Houston, Texas, États-Unis, 77024
- Victorium Clinical Research LTD CO
-
Splendora, Texas, États-Unis, 77372
- APD Clinical Research
-
Waxahachie, Texas, États-Unis, 75165
- ClinPoint Trials
-
-
Utah
-
Ogden, Utah, États-Unis, 84405
- Advanced Research Institute
-
-
Virginia
-
Newport News, Virginia, États-Unis, 23606
- Health Research of Hampton Roads, Inc.
-
-
West Virginia
-
Morgantown, West Virginia, États-Unis, 26505
- Frontier Clinical Research, LLC
-
-
Wisconsin
-
Kenosha, Wisconsin, États-Unis, 53144
- Clinical Investigation Specialist
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Be a male or female, age 18 to 70 years, inclusive, at the time of signing informed consent.
-
Participant has greater than a one-year history of migraine with or without aura as defined by International Conference on Harmonization (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated as documented in the participant's medical records from his/her treating physician and confirmed by the investigator.
-
Participant has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to screening (Visit 1).
-
Meet the following requirements:
-
Is a male OR
-
Is a female who is of non-childbearing potential defined by at least 1 of the following criteria:
-
Postmenopausal (aged >45 years and with a minimum of 12 months of spontaneous amenorrhea with a screening serum follicle-stimulating hormone (FSH) level in the menopausal range established for the central laboratory.
-
Post hysterectomy, bilateral oophorectomy or bilateral salpingectomy, based on the participant's recall of their medical history.
OR
-
Is a female of reproductive potential and:
-
agrees to remain abstinent from heterosexual activity*
*Abstinence can be used as the sole method of contraception if it is in line with the participant's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.
-
or agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the end of trial (EoT) visit. Acceptable methods of birth control are:
-
combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
- oral
- intravaginal
- transdermal
-
progestogen-only hormonal contraception associated with inhibition of ovulation:
- oral
- injectable
- implantable
-
intrauterine device (IUD)
-
intrauterine hormone-releasing system (IUS)
-
bilateral tubal occlusion
-
vasectomised partner
-
sexual abstinence
-
progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
-
male or female condom with or without spermicide
-
cap, diaphragm or sponge with spermicide
-
A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods)
-
This condition is waived if the participant is proven to have no child-bearing potential (eg, hysterectomy).
-
-
Participant voluntarily agrees to participate in the study by giving written informed consent.
-
Participant is able to read, understand and complete the study questionnaires and diary.
-
Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions.
-
Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study.
Exclusion Criteria:
-
Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study. Note: Participants must have a negative serum pregnancy test (β-human chorionic gonadotropin (β-hCG)) performed by the central laboratory prior to enrollment in the study and negative urine pregnancy result at the randomization visit.
Migraine history related
-
Participant has difficulty distinguishing his/her migraine attacks from tension-type headaches.
-
Participant has a history of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than two hours.
-
Participant has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the three months prior to screening (Visit 1).
-
Participant has brainstem (a.k.a. basilar-type) or hemiplegic migraine headache, or retinal migraine.
-
Participant was >50 years old at age of first migraine onset.
-
Participant is taking migraine prophylactic medication where the prescribed daily dose has changed during the 3 months prior to screening (Visit 1) or anticipates any change during the study. Any withdrawal of preventive medications for the treatment of migraine should be completed at least 30 days prior to screening.
Medical history related
-
Participant has, in the opinion of the investigator, other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, history of psychosis, dementia or significant neurological disorders other than migraine [participants who are currently being treated with non-prohibited medication for depression and symptoms are well controlled, in the opinion of the investigator, are eligible to participate in this study].
-
Participant is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Participants must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in the past 2 months or suicidal behavior in the past 6 months.
-
Has a recent history (within the past 3 years of the Screening Visit) or current diagnosis or evidence of endocrine, hematological, immunological, renal, respiratory, neurologic, gastrointestinal, biliary, or genitourinary abnormalities or diseases that, per the investigator's judgement, may jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.
-
Has a history of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed if they have received treatment and follow-up consistent with local standard of care.
-
Participant history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Participants with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening.
-
Has a history of human immunodeficiency virus disease.
-
Participant has a history of gastric or small intestinal surgery (including gastric bypass surgery or banding but not including cholecystectomy or appendectomy) or has a disease that causes malabsorption.
Laboratory, vital sign, and electrocardiogram (ECG) related
-
Has a positive test result at screening for hepatitis B surface antigen (Ag), hepatitis C virus antibody.
-
Has a screening estimated Glomerular Filtration Rate (eGFR) estimated with the Modification of Diet in Renal Disease (MDRD) equation of <45 ml/min/1.73 m^2.
-
Has a screening result for alanine aminotransferase or aspartate aminotransferase (ALT or AST) of >2.0X upper limit of normal (ULN) or total bilirubin >1.5X ULN at the Screening Visit. Note: An isolated bilirubin >1.5X ULN is acceptable if bilirubin is fractionated, and direct bilirubin is within the laboratory normal range.
-
Has a corrected QT interval to Fridericia's formula (QTcF) >450 milliseconds (msec) for males and >470 msec for females at screening.
-
Has a mean value for triplicate seated systolic blood pressure >160 mmHg and/or diastolic blood pressure (BP) >95 mmHg measured after at least 5 minutes at rest at the Screening Visit.
Note: If a participant's BP is exclusionary on the first triplicate assessment at the Screening Visit, they may have 1 repeat triplicate BP assessment at that visit after another rest of at least 10 minutes.
Medication use and substance abuse related
-
Has known history of or suspected abuse of alcohol or recreational drugs at screening.
-
Has use of soft drugs (such as marijuana or any substances containing tetrahydrocannabinol (THC) or cannabidiol (CBD)) within 3 months prior to screening, or hard drugs (such as cocaine, illicit narcotics/opiates) within 6 months prior to screening.
-
Has a positive drug screen at screening. Note: If benzodiazepines are detected on the drug screen, this is not exclusionary if they are prescribed a benzodiazepine for a therapeutic purpose (e.g. for insomnia) and confirmatory documentation is obtained from the prescribing physician.
-
Is currently in violation of study requirements for prohibited and permissible concomitant medications (not already specified in other criteria) or is anticipated to violate these requirements during study participation.
-
Has any use of prescription opiate medications within 14 days of screening or any anticipated/potential use of opiates during study participation.
-
History of use of ergotamine medications on greater than/equal 10 days per month on a regular basis for greater than/equal 3 months prior to screening.
-
History of non-narcotic analgesic intake on greater than/equal 15 days per month for greater than/equal 3 months prior to screening.
Other
-
Has known or suspected hypersensitivity to trial product(s) or related products.
-
Has a history of multiple significant and/or any severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.
-
Has any surgery scheduled for the duration of the trial.
-
Had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the Screening Visit; has a screening hemoglobin <11.0 g/dL (males) or <10.0 g/dL (females), or has a known hemoglobinopathy (e.g. sickle cell anemia, hemolytic anemia).
-
Has previous participation in this trial. Participation is defined as signed informed consent.
-
Has participated in any clinical trial of an approved or non-approved investigational biological medicinal product (e.g. antibody therapy) within 90 days of screening or has participated in any clinical trial of an approved or non-approved investigational small molecule medicinal product within 30 days or 5 half-lives (whichever is longer) of screening.
-
Has any other disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.
-
Is an employee or immediate family member (e.g., spouse, parent, child, sibling) of the Sponsor or study site.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Elismetrep (K-304) Dose Level 1
Participants received a single dose of elismetrep 2 mg |
Administered orally |
|
Expérimental: Elismetrep (K-304) Dose Level 2
Participants received a single dose of elismetrep 5 mg |
Administered orally |
|
Expérimental: Elismetrep (K-304) Dose Level 3
Participants received a single dose of elismetrep 10 mg |
Administered orally |
|
Expérimental: Elismetrep (K-304) Dose Level 4
Participants received a single dose of elismetrep 20 mg |
Administered orally |
|
Comparateur placebo: Placebo
Participants received a single dose of elismetrep-matched placebo |
Administered orally |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pain Freedom
Délai: 2 hours post-dose
|
Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) |
2 hours post-dose
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)
Délai: up to 7 days after administration of study therapy
|
up to 7 days after administration of study therapy
|
|
|
Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia)
Délai: 2 hours post-dose
|
Assessed using the number of evaluable participants that reported the absence of their MBS |
2 hours post-dose
|
|
Pain Relief
Délai: 2 hours post-dose
|
Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1). |
2 hours post-dose
|
|
Freedom From Photophobia
Délai: 2 hours post-dose
|
Assessed by tabulating the number of participants that reported the absence of photophobia at 2 hours post-dose in the subset of participants that reported the presence of photophobia at baseline. |
2 hours post-dose
|
|
Freedom From Phonophobia
Délai: 2 hours post-dose
|
Assessed by tabulating the number of participants that reported the absence of phonophobia at 2 hours post-dose in the subset of participants that reported the presence of phonophobia at baseline. |
2 hours post-dose
|
|
Freedom From Nausea
Délai: 2 hours post-dose
|
Assessed by tabulating the number of participants that reported the absence of nausea at 2 hours post-dose in the subset of participants that reported the presence of nausea at baseline. |
2 hours post-dose
|
|
The Probability of Requiring Rescue Medication
Délai: 24 hours post-dose
|
Assessed using the number of participants that took rescue medication within 24 hours after administration of study therapy |
24 hours post-dose
|
|
Sustained Pain Freedom
Délai: From 2 to 24 hours
|
Assessed using the number of participants that did not experience any headache pain through the time period of interest |
From 2 to 24 hours
|
|
Sustained Pain Relief
Délai: From 2 to 24 hours
|
Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest. |
From 2 to 24 hours
|
|
Sustained Pain Freedom
Délai: From 2 to 48 hours
|
Assessed using the number of participants that did not experience any headache pain through the time period of interest. |
From 2 to 48 hours
|
|
Sustained Pain Relief
Délai: From 2 to 48 hours
|
Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest. |
From 2 to 48 hours
|
|
Proportion of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)
Délai: Up to 7 days after administration of study therapy
|
Serious adverse events were assessed in the Safety Analysis Set. |
Up to 7 days after administration of study therapy
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- K-304 P001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .